Through our expertise in TLR biology we are developing compounds that can stimulate multiple innate mechanisms of tumor killing, potentially generating immune memory to antigens expressed by tumor cells. Our TLR agonists are specifically designed with the intention of stimulating multiple pathways of tumor killing through type 1 interferon induction and highly efficient stimulation of antigen presenting functions of plasmacytoid dendritic cells (PDC).
PDC are widely observed in tumors and are key components to the innate immune system. PDC express intracellular TLR9 which, upon stimulation, can produce large amounts of type 1 interferon. This innate immune response is the backbone of our approach to fighting cancer using our proprietary TLR agonists.